Epitalon vs MOTS-c.

Epitalon (also spelled Epithalon or Epithalone; sequence Ala-Glu-Asp-Gly, abbreviated AEDG) is a synthetic tetrapeptide developed in the 1980s by the Russian gerontologist Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology. It was designed to reproduce the proposed active fragment of Epithalamin, a crude peptide extract of the bovine pineal gland, and is classified as a short "peptide bioregulator." It is not a small-molecule drug or a hormone; the corresponding AEDG sequence was reported to be detectable in physiological pineal tissue only in 2017.

MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded within the 12S rRNA region of the mitochondrial genome, first described around 2015. It belongs to a small family of "mitochondrial-derived peptides" that appear to act as metabolic signaling molecules. It is an investigational research compound, not an approved drug, and is frequently grouped with longevity peptides where hype tends to outrun the evidence.

The most cited proposed mechanism is activation of telomerase: in cultured human somatic cells, Epitalon has been reported to induce telomerase reverse transcriptase expression, lengthen telomeres, and extend the number of cell divisions past normal replicative (Hayflick) limits. A second proposed mechanism is epigenetic/gene-regulatory: AEDG is a short, cell-penetrating peptide that is hypothesized to bind directly to specific DNA promoter regions and modulate transcription, with reported effects on melatonin-synthesis enzymes (e.g., AANAT), interleukin-2, and neuronal differentiation genes. It has also been described as modulating pineal melatonin output and as having antioxidant effects in animal and Drosophila models. Importantly, after roughly 25 years of research the authoritative 2025 review concludes the true mechanism of action remains unclear, and some findings (e.g., on melatonin secretion) directly conflict between studies.

In preclinical models MOTS-c is described as a stress-responsive signaling peptide: it has been reported to activate the AMPK energy-sensing pathway and to influence folate and methionine (one-carbon) metabolism, and under metabolic stress it can translocate to the cell nucleus where it is proposed to help regulate adaptive, antioxidant gene expression. These mechanisms are largely characterized in cell and animal systems; how faithfully they translate to a clinical effect in people is not established.

Most evidence is preclinical (cell culture, Drosophila, mice, and rats), where Epitalon and Epithalamin have shown telomere lengthening and antioxidant effects; in some rodent lifespan experiments from Khavinson's group, they also reduced tumor incidence and extended mean lifespan. Human data are far thinner and come almost entirely from the same Russian research network. The most-cited human report (Khavinson & Morozov, Neuro Endocrinol Lett 2003, PMID 14523363) describes a 6–8 year follow-up of 266 elderly subjects in which Epithalamin (the pineal extract, not synthetic Epitalon) and thymalin were associated with reduced mortality versus controls; a related 15-year follow-up was published in 2011 (PMID 22451889). There are also small open-label reports in retinitis pigmentosa and a circadian/melatonin study. These studies are open-label, often unblinded, frequently use the crude extract rather than the synthetic tetrapeptide, and have not been independently replicated by Western randomized controlled trials. The human-vs-preclinical gap is large and unresolved.

The evidence base is predominantly preclinical. The foundational study (Lee et al., Cell Metabolism, 2015) reported that MOTS-c promoted metabolic homeostasis and reduced obesity and insulin resistance in mice, and later work has linked it to exercise physiology and measured circulating levels in humans as a biomarker. However, there are no controlled human trials demonstrating that administering MOTS-c produces a meaningful clinical benefit. The gap between the animal/mechanistic data and proven human outcomes is large and should not be glossed over.

No rigorous, modern toxicology package exists for Epitalon. The 2025 International Journal of Molecular Sciences review explicitly states that data on this peptide's short- and long-term toxicity, genotoxicity, carcinogenic potential, and drug interactions are missing, and that these would be required before it could be approved as a pharmaceutical ingredient outside Russia. A specific theoretical concern is that a telomerase-activating compound could in principle promote survival or proliferation of abnormal cells, so its long-term oncologic safety in humans is genuinely unknown. Material sold for "research" use is unregulated, with no assurance of identity, purity, sterility, or endotoxin control. There are essentially no controlled human safety trials by Western standards.

Human safety is essentially uncharacterized. There are no published human toxicology, long-term, or drug-interaction data for administered MOTS-c. As an injectable compound sold research-use-only, the purity, identity, and sterility of non-pharmaceutical material are additional unknowns on top of the absent clinical safety package. It should be regarded as an experimental compound of unknown human risk.

Epitalon/Epithalamin reached clinical use only in Russia and has never been approved by the FDA or EMA; it is not an approved drug or dietary supplement in the United States and is sold there only as a research-use-only chemical. It is not a WADA-prohibited substance by name, though peptide-based agents can fall under broader anti-doping categories.

MOTS-c is not approved by the FDA (or any major regulator) for any indication and is not a recognized dietary supplement; it is an investigational, research-use-only compound with no registered human therapeutic trials.